Inactivation of AMPK alters gene expression and promotes growth of prostate cancer cells
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
AMP-activated protein kinase (AMPK) serves as a fuel-sensing enzyme that is activated by binding of AMP and subsequent phophorylation by upstream kinases such as the tumor suppressor LKB1, when cells sense an increase in the ratio of AMP to ATP. Acute activation of AMPK stimulates fatty acid oxidation to generate more ATP and simultaneously inhibits ATP-consuming processes including fatty acid and protein syntheses, thereby preserving energy for acute cell-surviving program, whereas chronic activation leads to inhibition of cell growth. The goal of the present study is to explore the mechanisms by which AMPK regulates cell growth. Toward this end, we established stable cell lines by introducing a dominant-negative mutant of AMPK α1 subunit or its shRNA into the prostate cancer C4-2 cells and other cells, or wild type LKB1 into the lung adenocarcinoma A549 and breast MB-MDA-231 cancer cells, both of which lack functional LKB1. Our results showed that the inhibition of AMPK accelerated cell proliferation and promoted malignant behavior such as increased cell migration and anchorage-independent growth. This was associated with decreased G1 population, downregulation of p53 and p21, and upregulation of S6K, IGF-1 and IGF1R. Conversely, treatment of the C4-2 cells with 5-aminoimidazole-4-carboxamide 1-D-ribonucleoside (AICAR), a prototypical AMPK activator, caused opposite changes. In addition, our study using microarray and RT–PCR revealed that AMPK regulated gene expression involved in tumor cell growth and survival. Thus, our study provides novel insights into the mechanisms of AMPK action in cancer cells and presents AMPK as an ideal drug target for cancer therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The protein kinase complement of the human genome
Manning, G., Whyte, D. B., Martinez, R., Hunter, T., & Sudarsanam, S. (2002) · Science · doi:10.1126/science.1075762 · Cited by 8,145
AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint
Gwinn, D. M., Shackelford, D. B., Egan, D. F., Mihaylova, M. M., Mery, A., Vasquez, D. S., Turk, B. E., & Shaw, R. J. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.003 · Cited by 3,849
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681 · cited 1×
“A recent study of genome-wide mutations in human lung adenocarcinomas has demonstrated that the EphA3 gene is mutated at a high frequency, suggesting that the mutated EphA3 acts as an oncogene (Ding et al., 2008).”
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388 · cited 1×
“Thus, treatment of type 2 diabetes with metformin significantly reduces the incidence of cancers (Evans et al., 2005).”
AMP-activated protein kinase induces a p53-dependent metabolic checkpoint
Jones, R. G., Plas, D. R., Kubek, S., Buzzai, M., Mu, J., Xu, Y., Birnbaum, M. J., & Thompson, C. B. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.03.027 · Cited by 1,619
Inoki, K., Ouyang, H., Zhu, T., Lindvall, C., Wang, Y., Zhang, X., Yang, Q., Bennett, C., Harada, Y., Stankunas, K., et al. (2006) · Cell · doi:10.1016/j.cell.2006.06.055 · Cited by 1,377
LKB1 modulates lung cancer differentiation and metastasis
Ji, H., Ramsey, M. R., Hayes, D. N., Fan, C., McNamara, K., Kozlowski, P., Torrice, C., Wu, M. C., Shimamura, T., Perera, S. A., et al. (2007) · Nature · doi:10.1038/nature06030 · Cited by 1,064 · cited 2×
“In addition, somatic mutations of the LKB1 gene have been found in several other cancers, for example, in 34% of lung adenocarcinomas, 19% of squamous cell carcinomas and other cancers (Su et al., 1999; Ikediobi et al., 2006; Ji et al., 2007).”
Dowling, R. J. O., Zakikhani, M., Fantus, I. G., Pollak, M., & Sonenberg, N. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2310 · Cited by 933 · cited 2×
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript TZDs and exercise) can inhibit tumor development (Buzzai et al., 2007; Dowling et al., 2007; Huang et al., 2008; Isakovic et al., 2007; Lee, 2003; Rattan et al., 2005; Xiang et al., 2004).”
Physical activity and cancer prevention–data from epidemiologic studies
LEE, I.-M. (2003) · Medicine & Science in Sports & Exercise · doi:10.1249/01.mss.0000093620.27893.23 · Cited by 436 · cited 2×
“A uthor M anuscript A uthor M anuscript A uthor M anuscript A uthor M anuscript TZDs and exercise) can inhibit tumor development (Buzzai et al., 2007; Dowling et al., 2007; Huang et al., 2008; Isakovic et al., 2007; Lee, 2003; Rattan et al., 2005; Xiang et al., 2004).”
AMPK, the metabolic syndrome and cancer
Luo, Z., Saha, A. K., Xiang, X., & Ruderman, N. B. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2004.12.011 · Cited by 426 · cited 13×
“…processes such as lipid and protein synthesis to preserve energy for cell surviving program (Hardie, 2007; Luoet al., 2005 Considerable amount of evidence has demonstrated that AMPK is implicated in the metabolic syndrome and cancer cell growth and metabolism (Hardie, 2007; Luo et al., 2005).”
InfluentialSelf-citationImportant role of the LKB1-AMPK pathway in suppressing tumorigenesis in PTEN-deficient mice
Huang, X., Wullschleger, S., Shpiro, N., McGuire, V. A., Sakamoto, K., Woods, Y. L., Mcburnie, W., Fleming, S., & Alessi, D. R. (2008) · Biochemical Journal · doi:10.1042/bj20080557 · Cited by 396
Development of a Novel Trans-Lentiviral Vector That Affords Predictable Safety
Wu, X., Wakefield, J. K., Liu, H., Xiao, H., Kralovics, R., Prchal, J. T., & Kappes, J. C. (2000) · Molecular Therapy · doi:10.1006/mthe.2000.0095 · Cited by 137 · cited 2×
“Lentivirus was prepared as described previously (Wu et al., 2000) Stable Cell Lines Prostate cancer C4-2 cells in 10% FBS-RPMI1640 medium, prostate cancer PC3 cells and lung cancer A549 cells in 10% FBS-Ham’s F12K medium, and breast cancer MDA-MB-231 cells in 10% FBS-DMEM medium were cultured in…”
MethodSelf-citation
Cited by
Mitochondrial Dysfunction Induces Senescence with a Distinct Secretory Phenotype
Wiley, C. D., Velarde, M. C., Lecot, P., Liu, S., Sarnoski, E. A., Freund, A., Shirakawa, K., Lim, H. W., Davis, S. S., Ramanathan, A., et al. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.11.011 · Cited by 1,275
“The AMPK-DN (D157A) (Zhou et al., 2009) cDNA was cloned into the DraI and XbaI sites of lentiviral vector 670-1 and packaged as described (Campeau et al.”
MethodThe androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesis
Massie, C. E., Lynch, A., Ramos‐Montoya, A., Boren, J., Stark, R., Fazli, L., Warren, A., Scott, H., Madhu, B., Sharma, N., et al. (2011) · The EMBO Journal · doi:10.1038/emboj.2011.158 · Cited by 624
AMPK As a Metabolic Tumor Suppressor: Control of Metabolism and Cell Growth
Luo, Z., Zang, M., & Guo, W. (2010) · Future Oncology · doi:10.2217/fon.09.174 · Cited by 383
Self-citationMitochondrial effectors of cellular senescence: beyond the free radical theory of aging
Ziegler, D. V., Wiley, C. D., & Velarde, M. C. (2015) · Aging Cell · doi:10.1111/acel.12287 · Cited by 354
Obesity, type 2 diabetes, and cancer: the insulin and IGF connection
Cohen, D. H., & LeRoith, D. (2012) · Endocrine-Related Cancer · doi:10.1530/erc-11-0374 · Cited by 301
Metadata
- Authors
- Zhou, J., Huang, W., Tao, R., Ibaragi, S., Lan, F., Ido, Y., Wu, X., Alekseyev, Y. O., Lenburg, M. E., Hu, G.-F., & Luo, Z.
- Venue
- Oncogene
- Published
- 2009-04-06
- Volume
- 28
- Issue
- 18
- Pages
- 1993-2002
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2001832472
- Cited by
- 112
- References
- 12
- FWCI
- 4.08
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.